Table 1.

Characteristics of patients treated

All patients (N = 256)Transplant (N = 147)No transplant (N = 109)P value
Age at treatment, y, median (range) 58 (18, 75) 54 (18, 75) 62 (21, 75) < .001 
D from diagnosis to initial treatment, median (range) 5 (1, 155) 5 (1, 155) 6 (1, 28) .23 
D from initial treatment to transplant, median (range)  118 (58, 621)   
Distance from hospital, median (range) 29.5 (2.4, 882) 27.4 (3.4, 882) 33.8 (2.4, 174) .12 
Male sex 131 (51%) 72 (49%) 59 (54%) .45 
Race    .027 
White 174 (68%) 102 (70%) 72 (66%)  
Black 67 (26%) 32 (22%) 35 (32%)  
Other 14 (6%) 12 (8%) 2 (2%)  
Ethnicity    .22 
Hispanic 26 (10%) 18 (12%) 8 (7%)  
Non-Hispanic 230 (90%) 129 (88%) 101 (93%)  
Diagnosis    .28 
AML 171 (67%) 93 (63%) 78 (26%)  
ALL 73 (28%) 45 (31%) 28 (71%)  
MDS 12 (5%) 9 (6%) 3 (3%)  
Risk categories in patients with AML    .044 
Intermediate risk 51 (30%) 34 (37%) 17 (22%)  
Poor risk 120 (70%) 59 (63%) 61 (78%)  
Risk categories in patients with ALL    .13 
Standard risk 14 (19%) 6 (13%) 8 (29%)  
Poor risk 59 (81%) 39 (87%) 20 (71%)  
Y of initial treatment    .61 
2016-2018 124 (48%) 69 (47%) 55 (50%)  
2019-2021 132 (52%) 78 (53%) 54 (50%)  
Number of survivors 139 101 38  
Survivor follow-up from initial treatment (mo), median (range) 35.0 (5.9, 76.8) 36.3 (5.9, 76.8) 28.3 (5.9, 73.6) .45 
All patients (N = 256)Transplant (N = 147)No transplant (N = 109)P value
Age at treatment, y, median (range) 58 (18, 75) 54 (18, 75) 62 (21, 75) < .001 
D from diagnosis to initial treatment, median (range) 5 (1, 155) 5 (1, 155) 6 (1, 28) .23 
D from initial treatment to transplant, median (range)  118 (58, 621)   
Distance from hospital, median (range) 29.5 (2.4, 882) 27.4 (3.4, 882) 33.8 (2.4, 174) .12 
Male sex 131 (51%) 72 (49%) 59 (54%) .45 
Race    .027 
White 174 (68%) 102 (70%) 72 (66%)  
Black 67 (26%) 32 (22%) 35 (32%)  
Other 14 (6%) 12 (8%) 2 (2%)  
Ethnicity    .22 
Hispanic 26 (10%) 18 (12%) 8 (7%)  
Non-Hispanic 230 (90%) 129 (88%) 101 (93%)  
Diagnosis    .28 
AML 171 (67%) 93 (63%) 78 (26%)  
ALL 73 (28%) 45 (31%) 28 (71%)  
MDS 12 (5%) 9 (6%) 3 (3%)  
Risk categories in patients with AML    .044 
Intermediate risk 51 (30%) 34 (37%) 17 (22%)  
Poor risk 120 (70%) 59 (63%) 61 (78%)  
Risk categories in patients with ALL    .13 
Standard risk 14 (19%) 6 (13%) 8 (29%)  
Poor risk 59 (81%) 39 (87%) 20 (71%)  
Y of initial treatment    .61 
2016-2018 124 (48%) 69 (47%) 55 (50%)  
2019-2021 132 (52%) 78 (53%) 54 (50%)  
Number of survivors 139 101 38  
Survivor follow-up from initial treatment (mo), median (range) 35.0 (5.9, 76.8) 36.3 (5.9, 76.8) 28.3 (5.9, 73.6) .45 

or Create an Account

Close Modal
Close Modal